A phase 1 clinical trial of H3B‐8800 has recently been initiated targeting patients with relapsed/refractory myeloid neoplasms (MDS, CMML, and AML) that carry splicing factor mutations (NCT02841540). Here, SLU7 is linked to myeloid neoplasm.